Hayato Koba
Overview
Explore the profile of Hayato Koba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, et al.
Lung Cancer
. 2025 Feb;
201:108422.
PMID: 39952082
Introduction: Use of pembrolizumab as first-line treatment in patients with non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥ 50 % was approved in Japan 5 years...
2.
Terada N, Koba H, Nanjo S, Kimura H, Nishiyama A, Yoneda T, et al.
Transl Lung Cancer Res
. 2024 Dec;
13(11):3067-3082.
PMID: 39670006
Background: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is widely used as a first-line treatment for -mutated non-small cell lung cancer (NSCLC). However, there is...
3.
Yamamura K, Hara J, Watanabe S, Kobayashi T, Kase K, Takeda Y, et al.
J Thorac Dis
. 2024 Apr;
16(3):2159-2166.
PMID: 38617783
Cough is a common and important sign/symptom in patients with idiopathic pulmonary fibrosis (IPF). However, there have been few reports focusing on cough, and the exact mechanisms for cough in...
4.
Abo M, Imamura K, Hosogi S, Kobayashi T, Takeda Y, Kase K, et al.
Respir Investig
. 2024 Mar;
62(3):419-425.
PMID: 38489921
Background: Ciliary beat frequency (CBF) is crucial in mucociliary clearance. High-speed video analysis (HSVA) is commonly used to measure CBF but lacks standardization. We compared visual observation and computer-assisted calculation...
5.
Koba H, Yoneda T, Morita H, Kimura H, Murase Y, Terada N, et al.
Thorac Cancer
. 2024 Feb;
15(8):661-666.
PMID: 38323355
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response...
6.
Tsukida S, Watanabe S, Hongo M, Murase Y, Yamamoto Y, Kase K, et al.
Chest
. 2023 Sep;
164(3):e71-e74.
PMID: 37689476
A 71-year-old woman sought treatment for a nonproductive cough. The patient had experienced no episodes of hemoptysis or shortness of breath. Her illness history included lumbago and dry mouth. The...
7.
Yoneda T, Sone T, Koba H, Shibata K, Suzuki J, Tani M, et al.
Clin Lung Cancer
. 2022 May;
23(6):467-476.
PMID: 35618628
Background: Immune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with...
8.
Koba H, Kimura H, Yoneda T, Ogawa N, Tanimura K, Tambo Y, et al.
Transl Lung Cancer Res
. 2022 Jan;
10(11):4161-4173.
PMID: 35004247
Background: Molecular targeted therapy has been developed as an innovative treatment for metastatic cancer. Epidermal growth factor receptor (EGFR) mutation is one of the most important and frequent oncogenic drivers...
9.
Koba H, Kimura H, Yoneda T, Sone T, Ohkura N, Hara J, et al.
Sci Rep
. 2021 Apr;
11(1):8398.
PMID: 33863951
In cancer patients, circulating cell-free DNA (cfDNA) includes tumor-derived DNA (tDNA). cfDNA has been used clinically for non-invasive gene mutation testing. The aim of this study was to characterize the...
10.
Takahashi W, Yoneda T, Koba H, Ueda T, Tsuji N, Ogawa H, et al.
Int J Infect Dis
. 2020 Nov;
102:529-531.
PMID: 33157292
Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis. This case...